Stable engraftment, as well as graft versus host disease‐free and relapse‐free survival brought by the combination of CD7 targeted universal chimeric antigen receptor‐T, and donor hemopoietic stem cells: Indication of a case report

• Published in: EJHaem 2024-06, Vol.5 (3), p.584-588
• Main Authors: Li, Shiqi, Yuan, Zhongtao, Liu, Lin, Li, Yu, Luo, Le, Peng, Lihui, Xu, Mengli, Yin, Ping, Chen, Yingnian, Li, Xiaoping, Zang, Qingying, Zhang, Xi, Wang, Sanbin
• Format: Article
• Language: English
• Subjects: allogeneic hemopoietic stem cell transplantation; Antigens; Bone marrow; CD7 antigen; Chimeric antigen receptors; Clinical trials; Cytokines; Graft versus host disease; Graft-versus-host reaction; Granulocytes; Hematopoietic stem cells; Intervention; Leukemia; Lymphatic leukemia; Lymphocytes; Lymphocytes T; Malignancy; Oxygen saturation; Peripheral blood; Prophylaxis; refractory; Remission; Short Report; Short Reports; Stem cell transplantation; Stem cells; T cell acute lymphoblastic leukemia; Transplants & implants; Tumor necrosis factor-TNF; universal CD7 targeted CAR‐T
• ISSN: 2688-6146; 2688-6146
• DOI: 10.1002/jha2.914

CD7 targeted CAR‐T has demonstrated potential in the treatment of T cell malignancies but no study has been reported about its potential in the prophylaxis of GVHD in allo‐HSCT. Here we reported a special case that a boy diagnosed with refractory acute T lymphoblastic leukemia (T‐ALL) was treated with universal CD7 targeted CAR‐T (CD7 UCAR‐T) and parent‐derived peripheral blood stem cells (PBSCs). Complete remission and full engraftment of donor was observed. In the later four months of follow‐up, in the absence of any immunodepression treatment, no signs of GVHD were observed. This case initially demonstrates the potential of CD7 UCAR‐T in the prophylaxis of GVHD.